GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annji Pharmaceutical Co Ltd (ROCO:7754) » Definitions » Buildings And Improvements

Annji Pharmaceutical Co (ROCO:7754) Buildings And Improvements : NT$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Annji Pharmaceutical Co Buildings And Improvements?


Annji Pharmaceutical Co Buildings And Improvements Historical Data

The historical data trend for Annji Pharmaceutical Co's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annji Pharmaceutical Co Buildings And Improvements Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Buildings And Improvements
- - - -

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24
Buildings And Improvements Get a 7-Day Free Trial - - - - -

Annji Pharmaceutical Co Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


Annji Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.

Annji Pharmaceutical Co Headlines

No Headlines